Atopic Dermatitis

While blue light irradiation was efficacious in reducing itch and IL-31 levels, it did not reduce any of the objective measures of AD.

The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.

Sanofi’s phase 3 program for amlitelimab in atopic dermatitis will start in early 2024.

Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.

This month's cover feature delves into the new applications and use of AI in dermatology and considers how AI can support clinicians rather than hinder them.

New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.

Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, share their approaches to educating patients on use of steroids for dermatologic conditions, highlighting how they approach pediatric patient populations.

Experts in dermatology discuss the benefits of improved topical steroidal vehicle excipients and their impact on treatment duration and response.

Linda F. Stein Gold, MD; Jayme M. Heim, MSN, FNP-BC; and Darren West, MPAS, PA-C, review the adverse effect profiles of steroidal and nonsteroidal treatments, focusing on hypothalamic pituitary adrenal axis suppression.

Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, comment on how steroids continue to fit into the topical treatment armamentarium.

Dermatologist Diego Ruiz Dasilva, MD, FAAD, and a patient with atopic dermatitis discuss the patient journey from initial symptoms to diagnosis to treatment selection.

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

The impact begins in utero, with the diet and health of the mother playing a key role in the potential for a child to develop diseases.

The grant will go toward supporting the group's project, "Atopic Dermatitis is More Than a Skin Disease: Raising Awareness and Improving Care."

Compared with the previous EczemaNet1, EczemaNet2 was more accurate in its automated detection of atopic dermatitis lesions.

This year’s virtual atopic dermatitis conference takes place on Sunday, December 10, 2023.

Colleen Cotton, MD, discusses the treatment landscape of pediatric atopic dermatitis, highlights from her session at Maui Derm NP+PA in Asheville, NC, and more.

Non-physician posts accumulated more than 3 times the number of views compared to those created by physicians. Among physicians, dermatologists demonstrated higher average view counts compared to non-dermatologists.

As cold weather is approaching for much of the country, it is crucial for dermatologists, pediatricians, and families to work together for proper pediatric atopic dermatitis care.

Experts in dermatology share their insights on how to approach corticosteroid hesitancy in their dermatology patient populations.

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C comment on the practical aspects of utilizing topical corticosteroids, including potency, formulation, administration, and utility.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C discuss the role of topical agents in the management of dermatological conditions reviewing their position and role within the treatment landscape for dermatological conditions.

No concerns were cited about the clinical data package, safety, or label of lebrikizumab.

Colleen Cotton, MD, does a deep dive on pediatric atopic dermatitis and explains the importance of timing and conversations with patients about different treatments.